Davern Capital Partners, LP
Davern Capital Partners, LP reported 15 US-listed holdings worth $586.5 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: BioNTech SE (12.0%), Roivant Sciences Ltd. (11.7%) and Royalty Pharma PLC (11.0%). Against the quarter before, it opened 3 positions, added to 10, trimmed 2 and sold out of 5.
The 14 largest of its 15 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +10.6% over the 2 quarters to 30 June 2026, against +9.5% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 3
- Alnylam Pharmaceuticals Inc ALNY$34.0 million
- Vera Therapeutics Inc. VERA$21.4 million
- Avalo Therapeutics Inc. AVTX$8.7 million
Added to 10
- BioNTech SE BNTX+449,495 shares · +147%
- Insmed Inc. INSM+377,262 shares · +207%
- Roivant Sciences Ltd. ROIV+1.1 million shares · +121%
- Royalty Pharma PLC RPRX+635,800 shares · +122%
- Ionis Pharmaceuticals Inc. IONS+411,806 shares · +106%
- Regeneron Pharmaceuticals, Inc. REGN+47,840 shares · +107%
- Structure Therapeutics Inc. GPCR+319,598 shares · +253%
- Mineralys Therapeutics Inc. MLYS+411,600 shares · +92%
and 2 more in the table below
Trimmed 2
- Natera Inc Com NTRA-24,991 shares · -17%
- Legend Biotech Corp. LEGN-123,226 shares · -9%
Sold out of 5
- Pfizer Inc. PFE$44.8 million last quarter
- argenx SE ARGX$25.6 million last quarter
- Eli Lilly & Co. LLY$25.1 million last quarter
- Abivax SA ABVX$8.7 million last quarter
- Viridian Therapeutics Inc. VRDN$5.9 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| BioNTech SE BNTX | 754.5K | $70.2 million | 11.97% | +449.5K |
| Roivant Sciences Ltd. ROIV | 1.9M | $68.4 million | 11.66% | +1.1M |
| Royalty Pharma PLC RPRX | 1.2M | $64.8 million | 11.05% | +635.8K |
| Ionis Pharmaceuticals Inc. IONS | 798.7K | $63.3 million | 10.80% | +411.8K |
| Insmed Inc. INSM | 559.8K | $59.7 million | 10.18% | +377.3K |
| Regeneron Pharmaceuticals, Inc. REGN | 92.6K | $57.8 million | 9.85% | +47.8K |
| Legend Biotech Corp. LEGN | 1.2M | $34.4 million | 5.87% | -123.2K |
| Alnylam Pharmaceuticals Inc ALNY | 113.1K | $34.0 million | 5.80% | new |
| Natera Inc Com NTRA | 119.0K | $32.3 million | 5.51% | -25.0K |
| Structure Therapeutics Inc. GPCR | 446.1K | $23.9 million | 4.08% | +319.6K |
| Mineralys Therapeutics Inc. MLYS | 858.8K | $23.2 million | 3.95% | +411.6K |
| Vera Therapeutics Inc. VERA | 498.8K | $21.4 million | 3.65% | new |
| Generate Biomedicines Inc. GENB | 824.7K | $13.9 million | 2.37% | +232.9K |
| Procept Biorobotics Corp. PRCT | 464.9K | $10.5 million | 1.79% | +203.7K |
| Avalo Therapeutics Inc. AVTX | 468.7K | $8.7 million | 1.48% | new |